First-line XELOX plus bevacizumab followed by XELOX plus bevacizumab or single-agent bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: The phase III MACRO TTD study
- Díaz-Rubio, E.
- Gómez-España, A.
- Massutí, B.
- Sastre, J.
- Abad, A.
- Valladares, M.
- Rivera, F.
- Safont, M.J.
- de Prado, P.M.
- Gallén, M.
- González, E.
- Marcuello, E.
- Benavides, M.
- Fernández-Martos, C.
- Losa, F.
- Escudero, P.
- Arrivi, A.
- Cervantes, A.
- Dueñas, R.
- López-Ladrón, A.
- Lacasta, A.
- Llanos, M.
- Tabernero, J.M.
- Antón, A.
- Aranda, E.
ISSN: 1083-7159, 1549-490X
Year of publication: 2012
Volume: 17
Issue: 1
Pages: 15-25
Type: Article